International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress

Milan 11 July 2020 - 15 July 2020

Two trials verify safety, efficacy of emicizumab for haemophilia A

18 Aug 2020 by

Two trials presented at ISTH 2020 attest to the safety and efficacy of the bispecific monoclonal antibody emicizumab as a prophylactic agent in people with haemophilia A (PwHA) with factor VIII (FVIII) inhibitors.

Two trials verify safety, efficacy of emicizumab for haemophilia A

18 Aug 2020

Low bleeding, VTE rates after 1-year edoxaban in real-world study

14 Aug 2020 by

The overall rates of bleeding and recurrent venous thromboembolism (VTE) were low across various subgroups after 12 months of edoxaban treatment in routine clinical practice, according to a non-interventional, post-authorization safety study of edoxaban — ETNA-VTE* presented during the ISTH 2020 Meeting.

Low bleeding, VTE rates after 1-year edoxaban in real-world study

14 Aug 2020

Personalized TAK-660 prophylaxis may prevent bleeds in severe haemophilia A

13 Aug 2020 by

Findings from the PROPEL* trial presented at ISTH 2020 suggest that a personalized prophylaxis with rurioctocog alfa pegol (TAK-660) may prevent bleeds in patients with severe haemophilia A.

Personalized TAK-660 prophylaxis may prevent bleeds in severe haemophilia A

13 Aug 2020

Apixaban tied to lower VTE risk in ambulatory cancer patients

13 Aug 2020 by

Treatment with apixaban led to a significantly reduced risk of venous thromboembolism (VTE) among ambulatory cancer patients who were undergoing chemotherapy, according to two post hoc analyses of the AVERT* trial presented at the ISTH 2020 Meeting.

Apixaban tied to lower VTE risk in ambulatory cancer patients

13 Aug 2020

Thrombotic complications in COVID-19 inpatients: updates from ISTH

07 Aug 2020 by

Thrombotic complications are rife among in-hospital patients with COVID-19, with patients in the ICU particularly at risk compared with those in the general wards, a study released at the ISTH 2020 Meeting has shown.

Thrombotic complications in COVID-19 inpatients: updates from ISTH

07 Aug 2020

Apixaban may confer survival benefit for COVID-19 inpatients

05 Aug 2020 by

The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.

Apixaban may confer survival benefit for COVID-19 inpatients

05 Aug 2020